Tofacitinib versus Methotrexate in Rheumatoid Arthritis | Zendy

Eun Bong Lee | Zendy; Roy Fleischmann | Zendy; Stephen Hall | Zendy; Bethanie Wilkinson | Zendy; John Bradley | Zendy; David Gruben | Zendy; Tamás Koncz | Zendy; Sriram Krishnaswami | Zendy; Gene V. Wallenstein | Zendy; Chuanbo Zang | Zendy; Samuel H. Zwillich | Zendy; Ronald van Vollenhoven | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

Author(s) -

Eun Bong Lee,

Roy Fleischmann,

Stephen Hall,

Bethanie Wilkinson,

John Bradley,

David Gruben,

Tamás Koncz,

Sriram Krishnaswami,

Gene V. Wallenstein,

Chuanbo Zang,

Samuel H. Zwillich,

Ronald van Vollenhoven

Publication year - 2014

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1310476

Subject(s) - tofacitinib , medicine , methotrexate , rheumatoid arthritis , janus kinase inhibitor , rheumatology , erythrocyte sedimentation rate , arthritis , gastroenterology , surgery

Methotrexate is the most frequently used first-line antirheumatic drug. We report the findings of a phase 3 study of monotherapy with tofacitinib, an oral Janus kinase inhibitor, as compared with methotrexate monotherapy in patients with rheumatoid arthritis who had not previously received methotrexate or therapeutic doses of methotrexate.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research